GlassScriptPhysician profile
Balu Gadhe
NPI 1740233808
$1,380.06
in general payments reported to CMS, 2019-2025
21 companies · $28.27 in 2025
The $28.27 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $315 · 2023: $373 · 2024: $382 · 2025: $28.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $282.93 | 2021-2024 | Aristada, Lybalvi |
| Bayer Healthcare Pharmaceuticals INC. | $144.45 | 2021-2022 | |
| Novo Nordisk INC | $136.11 | 2021-2024 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $106.02 | 2022-2024 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.53 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $75.89 | 2024 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $75.87 | 2023-2024 | Ingrezza |
| Lilly USA, LLC | $63.78 | 2021-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $61.51 | 2021-2022 | |
| Pfizer INC. | $53.21 | 2023 | |
| Lundbeck LLC | $48.44 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $44.67 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.56 | 2022 | |
| Amgen INC. | $28.27 | 2025 | Repatha |
| Bausch Health US, LLC | $20.94 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.60 | 2023 | Gvoke Hypopen |
| Corium, LLC | $19.40 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $19.24 | 2023 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $18.95 | 2021 | |
| Hologic Sales and Service, LLC | $18.31 | 2022 | |
| Glaxosmithkline, LLC. | $15.38 | 2024 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Balu Gadhe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.